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Abstract
Background: There is a need to develop potential new therapies for the management of diabetes and hypertension.
Australian medicinal plants collected from the Kuuku I’yu (Northern Kaanju) homelands, Cape York Peninsula, Queensland,
Australia were investigated to determine their therapeutic potential. Extracts were tested for inhibition of protein
glycation and key enzymes relevant to the management of hyperglycaemia and hypertension. The inhibitory activities
were further correlated with the antioxidant activities.
Methods: Extracts of five selected plant species were investigated: Petalostigma pubescens, Petalostigma banksii,
Memecylon pauciflorum, Millettia pinnata and Grewia mesomischa. Enzyme inhibitory activity of the plant extracts
was assessed against α-amylase, α-glucosidase and angiotensin converting enzyme (ACE). Antiglycation activity
was determined using glucose-induced protein glycation models and formation of protein-bound fluorescent
advanced glycation endproducts (AGEs). Antioxidant activity was determined by measuring the scavenging effect
of plant extracts against 1, 1-diphenyl-2-picryl hydrazyl (DPPH) and using the ferric reducing anti-oxidant potential
assay (FRAP). Total phenolic and flavonoid contents were also determined.
Results: Extracts of the leaves of Petalostigma banksii and P. pubescens showed the strongest inhibition of α-amylase
with IC50 values of 166.50 ± 5.50 μg/mL and 160.20 ± 27.92 μg/mL, respectively. The P. pubescens leaf extract was also
the strongest inhibitor of α-glucosidase with an IC50 of 167.83 ± 23.82 μg/mL. Testing for the antiglycation potential of
the extracts, measured as inhibition of formation of protein-bound fluorescent AGEs, showed that P. banksii root and
fruit extracts had IC50 values of 34.49 ± 4.31 μg/mL and 47.72 ± 1.65 μg/mL, respectively, which were significantly lower
(p < 0.05) than other extracts. The inhibitory effect on α-amylase, α-glucosidase and the antiglycation potential of the
extracts did not correlate with the total phenolic, total flavonoid, FRAP or DPPH. For ACE inhibition, IC50 values ranged
between 266.27 ± 6.91 to 695.17 ± 15.38 μg/mL.
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Conclusions: The tested Australian medicinal plant extracts inhibit glucose-induced fluorescent AGEs, α-amylase, α-
glucosidase and ACE with extracts of Petalostigma species showing the most promising activity. These medicinal plants
could potentially be further developed as therapeutic agents in the treatment of hyperglycaemia and hypertension.
Keywords: Phenolics, Flavonoids, Antioxidant activities, Antiglycation, α-amylase, α-glucosidase, Angiotensin
converting enzyme, Aboriginal, Traditional medicine, Local knowledge
Background
Type II diabetes mellitus is a chronic disease characterised
by high blood glucose level or hyperglycaemia. It is a
major health concern around the world with co-
morbidities such as obesity, hyperlipidemia, hypertension
and cardiovascular diseases [1]. Currently, 422 million
people worldwide are suffering from diabetes and this is
expected to reach 642 million by 2040 [2, 3]. In Australia,
3.2 million people live with Type II diabetes, and it is
known to be the 6th leading cause of death [2, 4]. For
Australian Indigenous peoples, rates of diabetes and high
blood sugar levels are between three and five times higher
than those of non-Indigenous Australians [5].
Non-insulin dependent hyperglycaemia characterises
the early stages of type II diabetes due to the increased
breakdown of starch by α-amylase and absorption of
glucose by α-glucosidase [6, 7]. The inhibition of these
enzymes can significantly decrease the postprandial in-
crease in blood glucose level after a mixed carbohydrate
diet, hence it is an important strategy for the manage-
ment of hyperglycaemia linked to type II diabetes [7]. In-
creasing evidence has shown that prolonged exposure to
elevated glucose induces the production of free radicals,
particularly reactive oxygen species (ROS) through glu-
cose autoxidation and protein glycation [8, 9]. Glycation
is a non-enzymatic reaction between free amino groups
of proteins and carbonyl groups of reducing sugars,
through the formation of Schiff bases. The unstable
Schiff bases further rearrange to produce reversible
Amadori products, promoting the formation of hetero-
geneous compounds collectively known as advanced gly-
cation endproducts (AGEs) [10, 11]. Protein glycation
plays significant roles in the initiation and progression of
micro and macro-vascular complications associated with
the pathogenesis of age-related diseases [10, 12]. The in-
teractions of AGEs with receptors of AGEs (known as
AGE-RAGE interactions) directly activate multiple intra-
cellular signalling, gene expression and the secretion of
pro-inflammatory molecules accompanied by increasing
free radicals that contribute towards pathologic compli-
cations related to diabetes such as atherosclerosis, ne-
phropathy, retinopathy and cataract [10–12]. One of the
long-term complications of type II diabetes is arterial
hypertension, which may eventually result in cerebrovas-
cular accidents and cardiovascular diseases.
Angiotensin I-converting enzyme (ACE) plays an
important part in the regulation of blood pressure and
normal cardiovascular functions by two different reac-
tions. It catalyses the conversion of angiotensin I to
angiotensin II and inactivates the vasodilator bradykinin,
which is conducive to lower blood pressure [13, 14]. In-
hibition of ACE is considered to be a useful therapy for
the control of blood pressure in hypertensive patients.
Various pharmacological approaches have been used
in the management of diabetes via different modes of
action such as: acarbose, miglitol, and voglibose which
inhibit α-amylase and α-glucosidase activity [15, 16];
aminoguanidine for antiglycation in alleviating diabetic
complications [17, 18]; and captopril which inhibits ACE
for the treatment of hypertension [19]. However, none of
the currently available inhibitors for clinical use are de-
void of severe side effects [16, 18]. Therefore, alternative
treatments including the use of traditional medicinal
plants are now becoming an attractive approach for the
treatment of postprandial hyperglycaemia and its related
complications [20–23].
Australia is classified as one of the world’s 17 megadi-
verse countries, possessing rich plant biodiversity, with
many species endemic to the continent [24]. Moreover,
Aboriginal people across Australia hold significant cus-
tomary medicinal knowledge associated with the use of
different plant species for indications including infec-
tion and inflammatory conditions [25]. The Cape York
Peninsula region in Far North Queensland is home to a
diverse range of medicinal plant species. An ongoing
collaborative research project exists between re-
searchers at University of South Australia and Trad-
itional Owners of the Northern Kaanju (Kuuku I’yu)
homelands in Cape York Peninsula, Queensland. This
research aims to improve social, health and economic
outcomes for the Aboriginal people linked to these
homelands through the development of medicinal plant
products [26]. It also seeks to protect and restore
biocultural diversity on homelands by bringing together
local and traditional knowledge held by Aboriginal
people with scientific knowledge [27]. Through investi-
gation of the activities of medicinal plants, the project
has potential to improve health outcomes for the
broader community through the discovery of new
therapeutic agents.
Deo et al. BMC Complementary and Alternative Medicine  (2016) 16:435 Page 2 of 11
We have previously investigated several plant species for
anti-inflammatory activities [25, 28] as Kuuku I’yu Trad-
itional Owners have used these plants for treating diseases
associated with inflammation [29]. Traditional medicinal
plants previously shown to have anti-inflammatory prop-
erties have also been reported to exhibit blood-glucose-
lowering and antiglycation effects [30–33]. In the present
study, we investigated the effect of selected Australian me-
dicinal plant extracts for α-amylase, α-glucosidase, and
ACE inhibition and antiglycation related to hypergly-
caemia. Correlations of the inhibitory activities with the




Folin-Ciocalteu, gallic acid, ascorbic acids, quercetin, butyl
hydroxyl toluene (BHT), 1,1-diphenyl-2-picrylhydrazyl
(DPPH), bovine serum albumin (BSA), aminoguanidine,
captopril, pancreatic α-amylase, yeast α-glucosidase
enzyme, p-nitrophenyl-α-D-glucopyranoside, acarbose,
furanacroloyl-Phe-Glu-Glu (FAPGG) and trichloroacetic
acid (TCA) were purchased from Sigma-Aldrich (Sydney,
Australia). All other chemicals used were of analytical or
HPLC grade.
Plant materials and extractions
Medicinal plants were collected on the Kuuku I’yu
homelands. The Kuuku I’yu (Northern Kaanju) or Kaani-
chi Pama are “inland” people belonging to the highlands
of central Cape York Peninsula, Northern Australia.
Their “homelands” (also called Ngaachi) encompass
some 840,000 hectares of diverse vegetation types. The
land contains natural features that have national and
international conservation significance. The Kuuku I’yu
people are inexorably linked to the land and its re-
sources which they value for their physical and spiritual
well-being. Today, people continue to utilize these
natural resources for their diet, cultural activities, and
medicine and healing [27].
The plant species examined in this study were selected
according to their medicinal uses as described as part of
local knowledge by the Kuuku I’yu Northern Kaanju Trad-
itional Owners (Table 1). Grewia mesomischa was formally
identified by David Halford, Queensland Herbarium.
Other plant species were formally identified by project
ethnobotanist (author Dr Nicholas Smith) and voucher
specimens were lodged and Western scientific names
confirmed at Queensland Herbarium, Brisbane, Australia
(Table 1).
Leaves, fruits, roots or bark were air dried in the shade
immediately after collection, loosely packed in paper
bags then transported to the laboratory for extraction.
Extractions were performed as previously described [28].
Briefly, samples were extracted for 24 h using 80 % (v/v)
ethanol. A solvent to plant material ratio of 10:1 was
used for leaves and fruit and a ratio of 5:1 was used for
roots/bark. After 24 h the first extract portion was re-
moved and a second equivalent volume of fresh solvent
was added to the plant material and allowed to extract
for a further 24 h. The second portion was then dec-
anted and the plant material was washed with 100 mL of
solvent. The combined ethanolic extracts and wash were
filtered using Whatman (#1) filter paper. The extract
was concentrated using a rotary evaporator under re-




Total phenolic content in the extracted samples was de-
termined as described elsewhere [7] with minor modifi-
cations. Briefly, sample extracts (0.5 mg/mL, 60 μL) and
Folin-Ciocateu’s reagent (60 μL) were mixed and
incubated at room temperature for 5 min. After incuba-
tion, 60 μL of Na2CO3 (10 % w/v) was added and the
reaction mixture was further incubated for 60 min at
room temperature in the dark. After incubation, the ab-
sorbance was measured at 760 nm. Gallic acid was used
as standard and phenolic content expressed as μg gallic
acid equivalents (GAE)/mg of sample weight.
Total flavonoid content
Flavonoid content in the extracted samples was estimated
according to a previous method [7]. Briefly, sample ex-
tracts (0.5 mg/mL, 50 μL) were mixed with aluminium
chloride solution (10 % (w/v), 20 μL), sodium acetate
(1 M, 20 μL) followed by absolute ethanol (150 μL). After
incubation for 30 min at room temperature in dark, the
absorbance was measured immediately at 450 nm.
Quercetin was used as standard and the results expressed
as μg quercetin equivalents (QE)/mg of sample weight.
In vitro antioxidant assays
Ferric reducing antioxidant potential (FRAP) assay
The ferric reducing activity of the extracts was estimated
based on a modified FRAP procedure described previ-
ously [34]. Sample extracts (0.5 mg/mL, 20 μL) were
mixed with 20 μL of 0.2 M potassium phosphate buffer
(pH 7.2) and potassium ferricyanide (1 % w/v, 20 μL)
followed by incubation at 50 °C for 20 min. After incu-
bation, TCA (10 % w/v, 20 μL), distilled water (75 μL)
and ferric chloride (0.1 % w/v, 20 μL) were added and
the reaction mixture was further incubated for 30 min at
room temperature in the dark. Absorbance was recorded
at 630 nm. Ascorbic acid (0–250 μg/mL) was used to de-
velop a standard curve and the results expressed as as-
corbic acid equivalents per mg sample (μg AAE/mg).
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1,1-diphenyl-2-picrylhydrazyl (DPPH) radical inhibition
DPPH radical scavenging method was determined by an
assay modified from da Silva Pinto et al. [35]. Sample ex-
tracts (0.5 mg/mL, 50 μL) and freshly prepared DPPH in
methanol (0.2 mM, 150 μL) were mixed and incubated
for 60 min at room temperature in the dark. After incu-
bation, absorbance was recorded at 490 nm. BHT
(0.5 mg/mL) was used as the positive control. DPPH ac-
tivity was expressed as a percentage (%) inhibition of
radical formation [35].
In vitro antiglycation assay
Antiglycation activity was determined using glucose-
induced protein glycation in vitro models. Aliquots
(250 μL) of BSA (10 mg/mL, final concentration) in
0.2 M phosphate buffer (pH 7.4, containing 0.02 % so-
dium azide) were pre-incubated with sample extracts
(50 μL, 0–500 μg/mL, final concentration) for 30 min at
room temperature. After pre-incubation, 200 μL of glu-
cose (100 mM final concentration) in 0.2 M phosphate
buffer (pH 7.4, containing 0.02 % sodium azide) were
added and the reaction mixture was incubated at 37 °C
for 3 weeks. After incubation, protein was extracted by
adding TCA (20 % w/v, 400 μL) to the glycated sample
and the reaction mixture was kept at 4 °C for 10 min be-
fore centrifugation (1000 × g) for 10 min. The pellet was
redissolved in alkaline phosphate buffer (0.2 M, pH 10,
2000 μL) and fluorescent AGEs were measured using a
multimode plate reader (EnSpire, PerkinElmer, USA). The
fluorescent intensity was measured at 370 nm (excitation)
and 440 nm (emission). Aminoguanidine (30 mM, final
concentration) was used as a positive control. The antigly-
cation was expressed as percentage inhibition of fluores-
cent AGE (%) = [(Fcontrol-Fsample)/Fcontrol)] × 100.
In vitro antidiabetic assays
Pancreatic α-amylase inhibition
The pancreatic α-amylase inhibition assay was modi-
fied from a previous study [21]. Different concentra-
tions of sample extracts (125 μL) were mixed with
125 μL of α-amylase solution (0.5 mg/mL in 0.1 M
sodium phosphate buffer, pH 6.9) and the reaction
mixture was pre-incubated at 37 °C for 10 min. After
pre-incubation, 25 μL of starch solution (1 % w/v)
was added every 10 seconds to a total of 125 μL. The
reaction mixture was further incubated at 37 °C for
20 min. After incubation the reaction was stopped by
adding 250 μL of dinitrosalicylic reagent (1 % 3,5-
dinitrosalicylic acid, 0.2 % phenol, 0.05 % Na2SO3 and 1 %
NaOH in aqueous solution) to the reaction mixture. The
reaction mixtures were heated at 100 °C for 10 min.
Thereafter, 250 μL of potassium sodium tartarate solution
(40 %) was added to the mixtures to stabilize the colour.
After cooling to room temperature, absorbance of the re-
action mixture was recorded at 540 nm. Acarbose (differ-
ent concentrations) was used as positive control. Results
were expressed as percentage (%) amylase inhibition
= [(AControl540-ASamples540nm)/AControl540nm)] × 100.
α-glucosidase inhibition
The α-glucosidase inhibition assay was modified from a
previous study [35]. Briefly, 50 μL of sample extracts
(different concentrations) were mixed with 100 μL of
yeast α-glucosidase enzyme (0.2 U/mL in 0.1 M potas-
sium phosphate buffer solution, pH 6.9) and incubated
at 37 °C for 30 min. After pre-incubation, 50 μL of p-ni-
trophenyl-α-D-glucopyranoside solution (5 mM) and the
reaction mixture were further incubated at 37 °C for
30 min. Sodium carbonate solution (0.1 M, 60 μL) was
added to the reaction mixture and incubated again at
37 °C for 20 min. Before and after incubation, absorb-
ance readings were recorded at 405 nm. Acarbose (0.25–
100 μg/mL) was used as a positive control. Results were
expressed as described for α-amylase inhibition.
Angiotensin converting enzyme (ACE) inhibition assay
The ACE inhibition assay was carried out using
furanacroloyl-Phe-Glu-Glu (FAPGG) as described previ-
ously [13]. ACE inhibition was evaluated using different
concentrations of sample extracts. The colour intensity
was measured at 340 nm. Captopril was used as a posi-
tive control.
Data analysis
All analysis was done in triplicates and each experiment
was repeated three times. Results were expressed as
Table 1 Different plant species and parts used in this study and local medicinal uses
Family Plant species name Part extracted Uses according to local medicinal
knowledge
Voucher number
Picrodendraceae Petalostigma banksii Britten & S.Moore Leaves, fruits, roots Toothache, mouth inflammation BRI AQ0737556
AQ0749696
Petalostigma pubescens Domin Leaves, fruits Toothache, mouth inflammation BRI AQ0737696
Melastomataceae Memecylon pauciflorum Blume var. pauciflorum Leaves Skin infection and inflammation BRI AQ0737545
Fabaceae Millettia pinnata (L.) Panigrahi Inner bark Skin sores, inflammation and pruritis BRI AQ0783017
Malvaceae Grewia mesomischa Burret Root bark Stomach ache BRI AQ0783018
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mean ± standard deviation (SD). The IC50 was defined as
the concentration of the samples causing 50 % inhibition
of enzymes and protein glycation and was estimated by
non-linear regression analysis using Graph Pad Prism
software (San Diego, CA, USA, Version 6.03). Differ-
ences were evaluated by one-way analysis of variance
(ANOVA) followed by Tukey’s multiple comparisons
test, and p < 0.05 was considered to be significant. Linear
regression analysis was determined with Pearson’s
correlation coefficient (r2) to compare the relationship
between antioxidants versus antiglycation properties;
and antioxidant activities versus enzyme inhibition
properties.
Results and discussion
Hyperglycaemia is still considered the principal cause of
diabetic complications attributed to increased produc-
tion of ROS, breakdown of starch by α-amylase, absorp-
tion of glucose by α-glucosidase and the formation of
AGEs, among others. Failure of existing antidiabetic
drugs due to complications and side effects are forcing
researchers to look for complementary medicines for
management of diabetes. In recent years, plant-derived
medicines worldwide have had a great deal of attention,
due to their antioxidant properties, enzyme inhibitory
activities, fewer side effects in comparison to conven-
tional medicines and their economic viability [36].
In Australia, the investigation of Aboriginal traditional
plant medicines for their potential to be developed into
therapeutic products is gaining momentum. However,
only a limited number of species have been extensively
studied. There has been limited previous research on
Australian Aboriginal medicinal plants for activity
against enzymes relevant to carbohydrate metabolism
[21, 37] and to our knowledge, no previous studies on
Australian medicinal plants for antiglycation activities
and inhibition of ACE. Our research is a collaboration
between Aboriginal and University-based researchers
with research into the efficacy and safety of their trad-
itional plant medicines driven and guided by Traditional
Owners. More broadly, our research aims to provide a
framework for addressing issues that arise when consid-
ering the development of Australian medicinal plants
into therapeutic products. This includes appropriate rec-
ognition of local and traditional knowledge and Indigen-
ous Intellectual Property ownership and, should plant
products be commercialised, the fair and equitable re-
turn of benefits back to the Traditional Owners [26].
In the current study, we investigated 80 % v/v aqueous
ethanol extracts of five plant medicines, Petalostigma
banksii (leaves, fruits and roots); Petalostigma pubescens
(leaves, fruits); Memecylon pauciflorum var. pauciflorum
(leaves); Millettia pinnata (inner bark); and Grewia
mesomischa (root bark) for antiglycation and inhibitory
potential against enzymes relevant to metabolic syn-
drome. The total phenolic flavonoid and the antioxidant
activities of the extracts were also determined and
correlated.
Total phenolic, total flavonoid and antioxidant potential
We first examined the extracts to determine their con-
tent of phenolics and flavonoids. Phenolic and flavonoid
compounds are secondary metabolites ubiquitously
found in different parts of plants that commonly exhibit
antioxidant activities. The total phenolic content of the
tested plant extracts ranged from 72.36 ± 15.84 to
347.87 ± 14.90 μg GAE/mg (Table 2). Among the leaves,
fruits and bark extracts, the highest total phenol content
was in P. banksii fruits, whereas M. pinnata inner bark
extracts had the lowest (Table 2). The extracts contained
flavonoids in the range from 3.36 ± 0.87 to 26.30 ±
2.75 μg QE/mg (Table 2). Interestingly, P. pubescens
fruits had the lowest flavonoid content, while the leaves
of the same plant had the second highest flavonoid con-
tent among the selected medicinal plants.
Antioxidant activity of the extracts was then assessed
using two different methods, the FRAP and DPPH as-
says. The effect of selected extracts on FRAP and DPPH
measured in this study are shown in Table 2 and Fig. 1,
respectively. FRAP, a measure of antioxidant power, de-
termines the reducing ability of an antioxidant reacting
with a ferric-tripyridyltriazine (Fe3+-TPTZ) complex to
form coloured ferrous-tripyridyltriazine (Fe2+TPTZ).
Test samples that favour reduction of the complex from
Table 2 Total phenolic, flavonoid and FRAP contents in the
selected Australian medicinal plant extracts







Leaves 333.70 ± 11.95e 14.66 ± 3.25b 449.98 ± 41.74d
Fruits 347.87 ± 14.90e 7.02 ± 4.49ab 453.14 ± 38.19d
Roots 323.53 ± 12.16e 19.38 ± 5.38bc 235.68 ± 9.36bc
Petalostigma pubescens
Leaves 276.96 ± 13.84d 22.64 ± 4.32c 453.30 ± 51.79d
Fruits 112.29 ± 5.34b 3.36 ± 0.87a 193.34 ± 7.01b
Memecylon pauciflorum var. pauciflorum
Leaves 140.24 ± 5.28b 26.30 ± 2.75c 311.42 ± 23.16c
Millettia pinnata
Inner bark 72.36 ± 15.84a 10.01 ± 4.05ab 26.46 ± 1.73a
Grewia mesomischa
Root bark 200.71 ± 5.52c 10.61 ± 3.83ab 214.52 ± 21.79b
Values are expressed as mean ± SD, n = 3
GAE Gallic acid equivalence, QE Quercetin equivalence, FRAP ferric reducing
antioxidant potential, AAE ascorbic acid equivalence
Data in the same column marked with different letters were significantly
different (p < 0.05)
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Fe3+-TPTZ to Fe2+-TPTZ, with indication of an intense
blue colour development confirms the presence of a re-
ductant ie., antioxidant [38]. FRAP values in the selected
sample extracts ranged from 26.46 ± 1.73 to 453.30 ±
51.79 μg AAE/mg (Table 2). P. banksii leaf and fruit ex-
tracts and the P. pubescens leaf extract were significantly
higher (p < 0.05) whereas the M. pinnata inner bark ex-
tract had the lowest FRAP values. The DPPH assay is a
measure of the reduction of alcoholic DPPH solution in
the presence of a hydrogen-donating antioxidant due to
the formation of a non-radical form, DPPH-H. In this
assay, the purple colour is reduced to a yellow coloured
diphenylpicrylhydrazine by the test sample containing
antioxidant [39]. For the tested extracts, all except M.
pinnata inner bark extract showed very high radical
scavenging activity (Fig. 1).
Several reports have shown that plant derived natural
products are effective free radical or active oxygen scav-
engers which are attributed to high levels of phenolics
and flavonoids [7, 40]. In this study, total phenolic and
flavonoid content were comparable to previous studies
reported on Australian food plants [41], but relatively
higher than the other Australian medicinal plants [21].
In the present study, the total phenolic content of the
medicinal plant extracts significantly correlated with
FRAP (r 2 = 0.7568, p < 0.001) and DPPH (r 2 = 0.5684,
p < 0.01), respectively (Table 3). However, there was
no correlation observed between the total flavonoid
content and FRAP or DPPH (Table 3). Differences in
correlations for antioxidant activity and flavonoid and
total phenolic content have been reported previously
[42]. The result may suggest that components other
than flavonoids are responsible for antioxidant effects.
α-amylase and α-glucosidase inhibition
Extracts were screened to examine their inhibitory activ-
ity to enzymes relevant to the management of diabetes.
A common therapeutic approach used in controlling
non-insulin dependent hyperglycaemia is through inhib-
ition of α-amylase and α-glucosidase that control the
breakdown and absorption of glucose and its precursors
in the small intestine. For α-amylase inhibition, IC50
values for the extracts ranged from 160.20 ± 27.92 to
310.17 ± 12.88 μg/mL (Table 4). The IC50 values for α-
amylase inhibition of P. banksii (leaves, fruits and roots),
P. pubescens (leaves and fruits) and M. pinnata (inner
bark) were significantly lower (p < 0.05) in comparison
to other sample extracts. For α-glucosidase inhibition,
IC50 values ranged from 167.83 ± 23.82 to 350.23 ±
24.05 μg/mL (Table 4). The IC50 values of P. banksii
(leaves, fruits), P. pubescens (leaves) and M. pinnata
Fig. 1 DPPH radical scavenging activity (%) of selected Australian medicinal plant extracts tested at 0.5 mg/mL. Values are expressed as means ±
SD, n = 3. Data marked with different letters were significantly different (p < 0.05). BHT = butyl hydroxyl toluene (positive control)
Table 3 Pearson’s correlations between total phenolic,
flavonoids contents and antioxidant activities of tested
Australian medicinal plant extracts
Antioxidant activities Pearson’s correlations (r2)
Total phenolic Total flavonoids
FRAP ability 0.7568b 0.2932
DPPH radical scavenging ability 0.5684a 0.1765
a, b indicate significance at p < 0.01 and p < 0.001 respectively
FRAP, ferric reducing antioxidant potential, DPPH 1,1-diphenyl-2-picrylhydrazyl
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(inner bark) extracts were significantly lower (p < 0.05)
than P. banksii (roots), P. pubescens (fruits), M. pauci-
florum (leaves) and Grewia mesomischa (root bark).
A previous study on medicinal plant extracts, re-
ported IC50 values for α-amylase ranging from 2070
to 13,740 μg/mL and α-glucosidase ranging from
2740 to 20,950 μg/mL [20]. These values are relatively
high in comparison to the extracts tested in the
present study and could be attributed to extraction tech-
niques. The IC50 values of enzyme inhibition presented in
our study were slightly higher compared to a previous re-
port on Australian medicinal plant extracts [21], but were
comparable to other medicinal plants [43, 44]. It has been
reported that polyphenols, flavonoids and the antioxidant
constituents of medicinal and food plants inhibit α-
amylase and α-glucosidase [7, 43, 44]. In the present
study, the IC50 values for both α-amylase and α-
glucosidase were poorly correlated with the total phenolic,
flavonoid, DPPH and FRAP (Table 5). The lack of correl-
ation between the total phenolics and enzyme inhibitory
activities has been previously reported [41, 45]. The
various relationships reported in the literature clearly
suggest that the total phenolics and their antioxidant cap-
acities do not define hyperglycaemia related enzyme inhib-
ition. This indicates the inhibitory actions of the tested
extracts on α-amylase and α-glucosidase may be mediated
by the action of constituents other than the phenolic and
flavonoid compounds.
Antiglycation
Extracts were assessed for inhibition of formation of
advanced glycation endproducts (AGEs) in a model of
protein glycation. AGEs are classified into two major
groups: fluorescent (pentosidine, crosslines, and imida-
zolones) and non-fluorescent (Nε-carboxymethyllysine
and Nε-carboxyethyllysine) [11, 12]. The formation of
AGEs occurs through multiple processes related in part
through ROS [9]. Medicinal plants have demonstrated
their ability to inhibit the process of protein glycation,
thus preventing alteration of the biological activity of pro-
tein, their degradation and conversion to AGEs [22, 23].
To our knowledge there are no reported studies on
Table 4 IC50 values of tested Australian medicinal plant extracts on fluorescent AGEs, α-amylase, α-glucosidase and ACE









Leaves 56.05 ± 6.10ab 166.50 ± 5.50a 167.83 ± 23.82a 266.27 ± 6.91a
Fruits 47.72 ± 1.65a 170.81 ± 6.45a 190.90 ± 19.93a 452.47 ± 38.51b
Roots 34.49 ± 4.31a 174.57 ± 5.36a 345.27 ± 16.33b 523.87 ± 14.46c
Petalostigma pubescens
Leaves 160.74 ± 3.86c 160.20 ± 27.92a 185.43 ± 14.05a 313.37 ± 29.33a
Fruits 83.52 ± 2.02b 187.90 ± 11.33a 348.13 ± 28.71b 597.53 ± 7.48c
Memecylon pauciflorum
Leaves 76.66 ± 14.50b 270.47 ± 17.48b 350.23 ± 24.05b 609.47 ± 30.92c
Millettia pinnata
Inner bark 71.48 ± 16.40b 188.63 ± 12.69a 183.83 ± 66.30a 695.17 ± 15.38e
Grewia mesomischa
Root bark 50.51 ± 6.77ab 310.17 ± 12.88c 299.30 ± 9.10b 630.33 ± 11.77d
Values are expressed as mean ± SD, n = 3
Data in the same column marked with different letters were significantly different (p < 0.05)
Table 5 Pearson’s correlations between the IC50 values for fluorescent AGEs, α-amylase, α-glucosidase and ACE versus total phenolic,
flavonoids contents and antioxidant activities of tested Australian medicinal plant extracts
Assays (IC50) Pearson’s correlations (r
2)
Total phenolics Total flavonoids FRAP DPPH
α-amylase inhibition −0.3905 −0.1191 −0.2948 −0.1758
α-glucosidase inhibition −0.3018 −0.1167 −0.3227 −0.3054
Fluorescent AGE inhibition −0.1594 −0.3205 −0.2393 −0.3460
ACE inhibition −0.7749b −0.2460 −0.8451b −0.5101a
a, b indicate significance at p < 0.05 and p < 0.001 respectively
FRAP ferric reducing antioxidant potential, DPPH 1,1-diphenyl-2-picrylhydrazyl, AGE advanced glycation endproducts, ACE Angiotensin converting enzyme
Deo et al. BMC Complementary and Alternative Medicine  (2016) 16:435 Page 7 of 11
antiglycation activities of Australian medicinal plants. In
the present study, an in vitro screening method was
employed to determine the inhibitory effects of extracts
on formation of fluorescent AGEs. The model system
used a high concentration of reducing sugar to speed up
the glycation process as glycation occurs very slowly under
physiological conditions. Phosphate buffer (0.2 M, pH 7.4)
increases the proportion of the open chain, reactive form
of the reducing sugar in solution thus favouring the kinet-
ics of protein glycation including formation of fluorescent
AGEs [46]. A temperature-time at 37 ± 1 °C for 3 weeks
was chosen to achieve minimally-modified protein under
physiological conditions and to prevent any deterioration
of the bioactive compounds in the plant extracts. Fluores-
cence intensity was determined using isolated protein with
appropriate dilution to reduce quenching effects of plant
extracts and coloured solutions due to glycation.
The antiglycation potential of the selected extracts were
compared on the basis of their IC50 values and ranged
from 34.49 ± 4.31 to 160.74 ± 3.86 μg/mL (Table 4). Of the
selected samples, P. banksii fruits and roots had signifi-
cantly lower (p < 0.05) levels, whereas P. pubescens leaves
showed the highest (p < 0.05) antiglycation IC50 value. In
P. pubescens, different plant components indicated differ-
ent levels of antiglycation potential (Table 4). This sug-
gests that the degree of antiglycation activities could vary
from plant to plant and in different tissues from the same
plant. It is suggested that the ability to reduce the forma-
tion of AGEs is closely related to the antioxidant proper-
ties of food and medicinal plants [22, 47]. Our studies
showed no correlation between the antiglycation potential
and the antioxidant activities (FRAP, DPPH) (Table 5).
This indicates the efficiency of antiglycation potential by
the tested extracts as an independent pathway rather than
their ability in scavenging free radicals formed during pro-
tein glycation. Other mechanism of antiglycation such as
blocking carbonyl or dicarbonyl groups in reducing
sugars, breaking the cross-link structures in the formed
AGEs and inhibiting the formation of late-stage Amadori
products have been reported through use of natural prod-
ucts [47, 48]. Further comprehensive studies of the
extracts tested in this study are required to evaluate the
antiglycation mechanisms described above.
ACE inhibitory activities
The plant extracts were also tested for ACE inhibitory
activities. ACE is another enzyme that has an impact on
metabolic syndrome - the stimulation of ACE causing
high blood pressure. Inhibition of ACE by medicinal
plant extracts to reduce hypertension has been previ-
ously reported [43, 44]. Recently effects of polyphenolic-
rich fractions of the native Australian herbs and foods
on ACE inhibition have been reported [41, 49], however,
to our knowledge the present study is the first to report
on the role of Australian medicinal plants on ACE in-
hibitory activities. For ACE inhibition, IC50 values
ranged between 266.27 ± 6.91 to 695.17 ± 15.38 μg/mL
(Table 3), with P. banskii leaves and P. pubescens leaves
showing comparable and higher ACE inhibitory activ-
ities. M. pinnata inner bark extracts showed significantly
(p < 0.05) lower ACE inhibitory activities. Results from
our studies were comparable to ACE inhibitory activities of
Lebanese traditional medicinal extracts reported previously
[44]. Further, another study with different extracts of
Gynura divaricata extracts has shown IC50 values for ACE
inhibition ranging from 370–1540 μg/mL [43]. In the
present study, a negative correlation between IC50
values of ACE inhibitory activities and total phenolics
(r2 = −0.775, p < 0.001), FRAP (r2 = −0.845, p < 0.001)
(Table 5) were seen in the tested extracts. In addition,
moderate negative correlation between IC50 values of
ACE inhibition and DPPH (r2 = −0.510, p < 0.05), but
not the flavonoid content were found (Table 5). P.
banksii leaves and P. pubescens leaves have shown
lower IC50 values for ACE inhibition than the previous
studies [43, 44], suggesting that a lower concentration
of these extracts can be used to obtain 50 % inhibition
of ACE. These results suggest that the Australian medi-
cinal plants could be further investigated for treating
hypertension through ACE inhibition.
Previous research on the tested plant species
There have been limited previous studies of the medicinal
activities of Australian species tested in this study. Extracts
of different parts of P. pubescens and P. banksii were
found to have promising antiglycation and enzyme inhibi-
tory activities which have not been previously reported.
Extracts of Petalostigma species including P. pubescens, P.
augustifolium and P. triloculare have previously been
found to exhibit antimicrobial activity [50, 51], however
very little is known of the chemistry of the genus. A GC-
MS analysis of a fruit extract of P. triloculare showed the
presence of low molecular weight compounds including
acetic acid, 2,2-dimethoxybutane, decane, undecane, 1,2-
benzenediol, 1,2,3-benzenetriol and benzoic acid [51]. The
heartwood of P. pubescens has also been shown to contain
diterpenoids including a cytotoxic diterpene (−)-sonderia-
nol [52]. Another species, P. sericea, has been found to
contain oleanolic acid [53]. No previous studies of this
genus have examined effects on carbohydrate metabolism,
antiglycation activities or ACE inhibition, and the possible
active constituents are unknown.
Various species in the genus Grewia have uses in trad-
itional medicine systems from a number of countries [54]
and some species have been studied for their antioxidant
effects. However there are no previous reports examining
the antioxidant and enzyme inhibitory of effects of the
Australian species G. mesomischa examined in this study.
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The species Memecylon pauciflorum occurs naturally in
Northern Australia and also occurs in SE Asia, southern
Malesia and New Guinea [55]. Other Memecylon species
used in traditional medicine in India including those
reported as Memecylon umbellatum, M. talbotianum,
M. edule and M. malabaricum have been studied for
their medicinal effects including antioxidant [56, 57],
anti-inflammatory [58, 59] and in vivo antidiabetic
effects [60].
Millettia pinnata (synonym Pongamia pinnata) has a
broad distribution from India, through central and south-
eastern Asia, Indonesia and into northern Australia. M.
pinnata grown in India has been studied for a number of
activities. An extract of the leaves of the plant collected in
Tamil Nadu, India was recently found to have moderate
antioxidant activity and significant nitric oxide scavenging
activity [61]. The total phenolic content of the leaf extract
of M. pinnata was reported in that study as 4.1 ± 1.5 mg/g
(μg/mg), lower than the total phenolic content of inner
bark extract reported in our study (Table 2). Extracts of
the stem bark have been shown to have antihyperglycae-
mic activity in diabetic mice and recently have been
shown to decrease blood glucose levels, and improve
electrocardiographic and hemodynamic parameters and
improve oxidative stress in a model of cardiomyopathy
in diabetic rats [62]. The stem bark extract has been
shown to contain alkaloids, terpenoids (including triter-
penes), steroids, flavonoids and volatile oils, with the
isolated triterpenoid cycloart-23-ene-3β, 25-diol (B2)
possessing antidiabetic activity and antioxidant activity
in diabetic animals [63]. The bark has also been shown
to have in vitro wound healing activity [64]. As M. pin-
nata has been noted to be a variable species and a
number of varieties [65] it would of interest to further
compare the medicinal activities and chemistry of M.
pinnata native to northern Australia with that in other
countries.
The plant extracts examined in this study, in particu-
lar the Petalostigma species tested, show potential for
development as herbal or functional food products for
the management or prevention of hyperglycaemia and
its related complications. Further research is now
needed to focus on isolation and characterization of
bioactive compounds from these medicinal plants. This
will be important for standardisation of the extracts
and further understanding of the mechanisms under-
lying inhibition of protein glycation. While these
extracts have long history of traditional use for inflam-
matory symptoms there is also a need to further evalu-
ate their safety as part of any product development.
Conclusion
This study reports for the first time on the potential of
selected Australian medicinal plant extracts to inhibit
protein glycation and enzymes related to hyperglycaemia
and hypertension. The evidence produced in this study
is useful to design further studies and investigate the
antiglycation agents for the management of diabetic
complications in vivo.
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